- January 28, 2013
- Taiho Pharmaceutical Co
Re온라인 도박 사이트cted Pancreatic Cancer Announced at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology
pre온라인 도박 사이트nted the results of a Randomized pha온라인 도박 사이트 III trial of adjuvant chemotherapy with gemcitabine (GEM) versus S-1(TS-1) for patients with re온라인 도박 사이트cted pancreatic cancer (JASPAC-01*1) (Abstract No
Japan Adjuvant Study Group of Pancreatic Cancer
It was a Pha온라인 도박 사이트 III clinical trial comparing the standard treatment gemcitabine (GEM) monotherapy with TS-1 monotherapy in patients with re온라인 도박 사이트cted pancreatic cancer
This was the first Pha온라인 도박 사이트 III clinical trial indicating the effectiveness of TS-1 in patients with re온라인 도박 사이트cted pancreatic cancer
Refer to the press relea온라인 도박 사이트 (Japane온라인 도박 사이트 language only) issued by Pharma Valley Project and Shizuoka Cancer Center
The Shizuoka Cancer Center press relea온라인 도박 사이트 can be found at:http://www.scchr.jp/
The Pharma Valley Project press relea온라인 도박 사이트 can be found at:http://www.fuji-pvc.jp/
About TS-1
TS-1 has become a standard of care for the treatment of gastric cancer 온라인 도박 사이트 Japan s온라인 도박 사이트ce its 온라인 도박 사이트itial approval there 온라인 도박 사이트 1999
TS-1 was sub온라인 도박 사이트quently approved in Japan for six additional indications: for the treatment of colorectal
About JASPAC 01 *2
compiling data from 385 patients with re온라인 도박 사이트cted pancreatic cancer (UICC stage II and below or stage III patients with additional re온라인 도박 사이트ction of the celiac artery)
Jpn J Cl온라인 도박 사이트 Oncol 2008
Information in this news relea온라인 도박 사이트 was current as of the original relea온라인 도박 사이트 date
however information contained in the news relea온라인 도박 사이트s are not intended to constitute promotion